Paper Details

  1. Home
  2. Paper Details

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Author: GirardetJean-Luc, HagertyDavid T, HyndmanDavid, IversonCory, LiuSha, ManhardKimberly, MinerJeffrey N, NanavatiPayal, QuartBarry, ShenZancong, TanPhilip K, TerkeltaubRobert, YehLi-Tain

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lesinurad is a new drug for gout that inhibits URAT1, a transporter involved in uric acid excretion. It offers a potential alternative to current treatments with fewer side effects and drug interactions.
Paper Details　
Original Abstract of the Article :
Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone are used as g...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048659/

データ提供：米国国立医学図書館（NLM）

Lesinurad: A Novel Treatment for Gout Targeting Renal Urate Transporters

Gout is a painful inflammatory condition caused by the accumulation of uric acid in the body. This study examines the mechanism of action of lesinurad, a novel drug for treating gout. The research found that lesinurad effectively reduces serum uric acid levels by inhibiting urate transporters in the kidney, offering a new therapeutic target for gout management.

Lesinurad: A Targeted Approach to Gout Treatment

The study reveals that lesinurad, a novel URAT1 inhibitor, effectively reduces serum uric acid levels by inhibiting urate transporters in the kidney. This research underscores the potential of targeting renal urate transporters as a therapeutic strategy for gout management.

A Camel's Journey: Finding the Source of Uric Acid Accumulation

This study sheds light on the mechanism of action of lesinurad, a novel treatment for gout. Think of it as a camel navigating a desert, searching for the source of uric acid accumulation and finding a way to control its flow.

Dr. Camel's Conclusion

This study highlights the potential of lesinurad as a new and effective treatment for gout. The drug's mechanism of action, targeting renal urate transporters, offers a promising approach for reducing serum uric acid levels and managing gout symptoms.
Date :
  1. Date Completed 2017-11-08
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

27716403

DOI: Digital Object Identifier

PMC5048659

Related Literature

Article Analysis
・Effects of lesinurad
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.